TIANJIN, China, Sept. 28, 2026 /PRNewswire/ -- September 25–27, MHTE 2026 was held in Ulaanbaatar. Perennial General Hospital Tianjin, together with Tianjin Hospital, Tianjin Chest Hospital, and Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, formed a medical delegation to attend under the theme "International Diagnosis and Treatment • Tianjin Solutions — Building a Health Bridge on the China-Mongolia-Russia Economic Corridor."

Perennial General Hospital Tianjin is China's first wholly foreign-owned tertiary general hospital. Located in Tianjin Perennial Health City, the world's first medical, rehabilitation, eldercare, wellness, and cultural tourism high-speed rail TOD complex, it covers general hospitals, rehabilitation hospitals, brain hospitals, large health communities, and hotel clusters, committed to building an international, high-standard, full-cycle healthcare service platform. It has treated over 500 international patients from 41 countries and regions, including many from Mongolia.

This roadshow focuses on direct doctor-to-doctor exchanges, establishing specialty connections through academic lectures, case discussions, and second opinions, and provides Mongolian patients with evaluation, treatment, and follow-up support for seeking medical care in Tianjin, gradually forming a sustainable cross-border diagnosis and treatment channel. The expert delegation also held talks with Mongolian Trade and Development Bank, IWFCI Mongolia Chapter, and other institutions to explore group health checkups and follow-up specialty care cooperation models.

For more information, please visit: https://www.perennialgeneralhospital.com.cn/

Share this article

MOYOM Biotech Secures Financing from Cathay Capital to Accelerate Global Growth in Regenerative Aesthetics

SHANGHAI, Sept. 28, 2026 /PRNewswire/ -- MOYOM Biotech, a biotechnology company specializing in regenerative aesthetic biomaterials, today announced that it has completed a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital. The investment marks an important milestone in the company's development and will support its next phase of global growth.

The fund was jointly established by Cathay Capital, L'Oréal and the Shanghai Jing'an District Government to foster innovation in beauty, health and skin science. Cathay Capital has built a global investment ecosystem spanning consumer, healthcare and technology, with notable investments including Moonshot AI (Kimi), autonomous driving company Momenta, U.S. fintech company Chime, digital asset platform Ledger, global delivery platform Glovo and AI biotechnology company Owkin.

In addition to identifying emerging brands, investment platforms of this kind can give strategic partners earlier access to emerging technologies, supply-chain capabilities and innovation in adjacent industries. Cathay Capital's investment in MOYOM reflects growing interest in technologies and biomaterial innovations with the potential to shape the next generation of the beauty and medical aesthetics industry.

Founded in 2018, MOYOM focuses on nanomedical biomaterials and Class III absorbable implantable medical devices, particularly calcium hydroxylapatite (CaHA) regenerative materials. Its flagship brand, Aphranel®, brings MOYOM's proprietary biomaterials research to market. Positioned as a new-generation CaHA biostructurer, Aphranel® is designed to combine immediate structural support, regenerative stimulation and complete biodegradation.

MOYOM's technology platform is built around two proprietary technologies: ACD-MT® raspberry-shaped through-hole CaHA microspheres and PCD-ETT® physically cross-linked CMC gel technology. Together, they are engineered to deliver structural performance, support regenerative interaction and enable controlled biodegradation.

Aphranel® received Class III medical device registration from China's National Medical Products Administration (NMPA) in February 2025 and certification under the European Union Medical Device Regulation (EU MDR) in May 2026, establishing a regulatory foundation for international expansion. Since its commercial launch in May 2025, Aphranel® has been introduced in more than 700 medical aesthetics clinics across China, demonstrating increasing market adoption alongside continued scientific and regulatory progress.

With its proprietary technology platform, key regulatory milestones and growing market presence, MOYOM is entering a new phase of growth. Leveraging Cathay Capital's global ecosystem, the company plans to accelerate clinical translation, pursue additional regulatory approvals and expand into overseas markets, while continuing to invest in next-generation regenerative biomaterials.

The financing will support MOYOM's efforts to bring biomaterial innovation originating in China to international markets and establish Aphranel® as a science-driven regenerative aesthetics brand with global reach.

About MOYOM Biotech

Founded in 2018, MOYOM Biotech develops regenerative aesthetic biomaterials and absorbable implantable medical devices. The company developed Aphranel®, its flagship CaHA-based regenerative aesthetics brand.

SOURCE MOYOM Biotech

Share this article

CALGARY, AB, Sept. 28, 2026 /PRNewswire/ -- High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that it placed No. 315 out of 375 companies listed on the 2026 Report on Business ranking of Canada's Top Growing Companies, with a verified three-year revenue growth rate of 66% over the 2022 to 2025 measurement period. Highlighting the Company's increasing profitability profile, Adjusted EBITDA was also up 161% during this period.1

_______________________

1 Adjusted EBITDA is a non-IFRS financial measure

"Six consecutive years on this list is a milestone our entire team should be proud of. We have grown Canna Cabana into Canada's largest cannabis retail chain, built a deeply loyal customer base and more than doubled Adjusted EBITDA over the three-year period measured. We have done it by staying focused on value for our customers and disciplined execution across the business," said Raj Grover, Founder and Chief Executive Officer of High Tide.

"The business is moving with even greater momentum today. Following our strongest quarter yet, we are approaching an $800 million annualized revenue run rate, while Remexian is adding a significant new source of growth in Germany. With a strong foundation, a proven growth strategy and significant opportunities ahead, we are more energized than ever about the next phase of High Tide's growth. As always, I extend my deepest gratitude to our entire team, our ELITE and Cabana Club members, and our shareholders for their continued support," added Mr. Grover.

Canada's Top Growing Companies is an editorial ranking that was launched in 2019 to celebrate the achievements of innovative businesses in Canada. To qualify for this voluntary program, companies had to complete an in-depth application process and fulfill revenue requirements. In total, 375 companies earned a spot on this year's ranking. The full list of 2026 winners along with editorial coverage is published in the October issue of Report on Business magazine. The list is also published online here.

ABOUT HIGH TIDE

High Tide Inc. is the leading community-grown, retail-forward cannabis enterprise engineered to unleash the full value of the world's most powerful plant. Its wholly owned subsidiary, Canna Cabana, is the second-largest cannabis retail brand globally. High Tide (HITI) is uniquely-built around the cannabis consumer, with wholly-diversified and fully-integrated operations across all components of cannabis, including:

Retail: Canna Cabana™ is the largest cannabis retail chain in Canada, with 232 domestic and 1 international location. The Company's Canadian bricks-and-mortar operations span British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario. Excluding British Columbia, where store counts are capped at 8, the Company holds a growing 14% share of the market. In 2021, Canna Cabana became the first cannabis discount club retailer in the world. In 2025, the Company became the first North American cannabis operator to launch a bricks-and-mortar presence in Germany. The Company also owns and operates multiple global e-commerce platforms offering accessories and hemp-derived products.

Medical Cannabis Distribution: Remexian Pharma GmbH is a leading German pharmaceutical company, with a 10.5% share of the German medical cannabis market, built for the purpose of importation and wholesale of medical cannabis products at affordable prices. Among all German medical cannabis procurers, Remexian has one of the most diverse reaches across the globe and is licensed to import from 22 countries including Canada.

High Tide consistently moves ahead of the currents, having been named one of Canada's Top Growing Companies by the Globe and Mail's Report on Business in 2026 for the sixth consecutive year and was recognized as a top 50 company by the TSX Venture Exchange (the "TSXV") in 2022, 2024 and 2025. High Tide was also ranked number one in the retail category on the Financial Times list of Americas' Fastest Growing Companies for 2023. To discover the full impact of High Tide, visit www.hightideinc.com. For investment performance, don't miss the High Tide profile pages on SEDAR+ and EDGAR.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities laws. Forward-looking information in this press release includes, but is not limited to, statements regarding the Company's expectations concerning the continued growth and development of its Canadian retail cannabis operations and German medical cannabis distribution business, the continued strengthening of Canna Cabana's position in Canada, the continued scaling of Remexian's operations in Germany and the Company's future growth and operating performance.

Forward-looking information is based on the Company's current expectations, estimates, projections, assumptions and beliefs as of the date of this press release. Material assumptions include assumptions regarding continued consumer demand for the Company's products and services; the Company's ability to maintain and expand its retail and distribution operations; the performance of Canna Cabana and Remexian; the availability of product supply; the Company's ability to retain required licences and regulatory authorizations; prevailing competitive, economic and market conditions; and the absence of material adverse changes in applicable laws or the Canadian and German cannabis markets.

Forward-looking information is subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements to differ materially from those expressed or implied by such information. These risks and uncertainties include, among others, changes in consumer demand; competition; changes in cannabis laws, regulations or licensing requirements in Canada or Germany; the Company's ability to execute its growth strategy; supply-chain disruption; the availability and cost of capital; inflationary and other cost pressures; foreign exchange fluctuations; the performance and integration of acquired businesses; and the other risks described under the heading "Non-Exhaustive List of Risk Factors" in Schedule A to our current annual information form and in the Company's other continuous disclosure filings available under its profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

Readers are cautioned not to place undue reliance on forward-looking information. Although the Company believes that the expectations and assumptions reflected in such information are reasonable, there can be no assurance that they will prove to be correct. The forward-looking information in this press release speaks only as of the date of this press release. The Company undertakes no obligation to update or revise such information to reflect new events or circumstances, except as required by applicable law.

CONTACT INFORMATION

Media Inquiries

Omar Khan

Chief Communications and Public Affairs Officer

High Tide Inc.

[email protected]

403-770-3080

Investor Inquiries

Vahan Ajamian

Capital Markets Advisor

High Tide Inc.

[email protected]

SOURCE High Tide Inc.

Share this article

The trade underlines the important role of Argus differential assessments in west African crude price discovery and the market's drive for greater transparency

LONDON, Sept. 28, 2026 /PRNewswire/ -- Oil traders have initiated the first west African (WAF) crude cargo transaction on the Argus Open Markets® (AOM®) platform, marking a significant step forward in the development of more transparent, auditable and efficient price discovery for physical crude markets.

The deal was initiated on the WAF crude AOM stack. TotalEnergies accepted the offer of a Nigerian Qua Iboe crude cargo at a premium of $4.10/bl to Dated Brent for a 950,000 bl cargo. The deal represents an estimated value of more than $115mn.

Global energy and commodity price reporting agency Argus operates AOM platforms across a range of markets, enabling registered participants to post bids and offers, discover counterparties and initiate transactions within a transparent and auditable framework.

This first deal builds on growing industry engagement with the west African crude AOM platform, where major producers, traders and refiners have increasingly used the screen to show value, test liquidity and contribute observable information to the Argus price assessment process.

West African grades are usually traded as differentials to other outright-price crude benchmarks, making robust, trusted and accurate differential assessments critical to commercial decision-making. Argus' west African crude differentials are widely referenced by market participants seeking to understand the relative value of Nigerian, Angolan and other regional grades in an increasingly competitive Atlantic basin market.

Historically, much of the physical crude market has relied on bilateral negotiations, which can make price discovery fragmented and difficult. AOM has the potential to change that by bringing bids, offers and trade initiation into a single visible venue, while preserving the bilateral nature of physical negotiations and allowing companies to help shape the value of important regional crude differentials in real time.

Argus Media chairman and chief executive Adrian Binks said: "The first initiated WAF crude trade on the Argus Open Markets platform is an important milestone for price discovery and comes as west African crude is increasingly in demand in markets both east and west of the region, as buyers seek alternatives for lost Mideast Gulf supplies. West African crude differentials are central to how the market prices and compares different grades, and we are pleased to support market participants with a transparent, auditable platform that complements Argus' long-established assessment process. This transaction underlines the industry's appetite for greater transparency and reinforces the important role Argus plays in bringing robust price information to global crude markets."

Argus contact information

London: Seana Lanigan

+44 20 7780 4200

Email Seana

Houston: Elizabeth Frye

+1 713 968 0000

Email Elizabeth

Singapore: Tomoko Hashimoto

+65 6496 9960

Email Tomoko

About Argus Media

Argus is the leading independent provider of market intelligence to the global energy and commodity markets. We offer essential price assessments, news, analytics, consulting services, data science tools and industry conferences to illuminate complex and opaque commodity markets.

Headquartered in London with over 1,500 staff, Argus is an independent media organisation with 32 offices in the world's principal commodity trading hubs.

Companies, trading firms and governments in 160 countries around the world trust Argus data to make decisions, analyse situations, manage risk, facilitate trading and for long-term planning. Argus prices are used as trusted benchmarks around the world for pricing transportation, commodities and energy.

Founded in 1970, Argus remains a privately held UK-registered company owned by employee shareholders and global growth equity firm General Atlantic.

Trademark notices

ARGUS, the Argus Logo, ARGUS MEDIA and ILLUMINATING THE MARKETS, Argus publication titles and index names are trademarks of Argus Media Limited. Visit Trademarks for more information.

SOURCE Argus Media

Share this article

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Infrastructure Capital Advisors, LLC (Infrastructure Capital), a leading provider of investment management solutions designed to meet the needs of income-focused investors, is excited to declare distributions for the Infrastructure Capital Nasdaq Option Income ETF (QVOL), Infrastructure Capital Bond Income ETF (BNDS), Infrastructure Capital Small Cap Income ETF (SCAP), and Infrastructure Capital Equity Income ETF (ICAP). QVOL has declared a distribution increase by $0.05 from $1.04 to $1.09 per share. SCAP has declared a distribution increase by $0.005 from $0.25 to $0.255 per share. ICAP has declared a distribution increase by $0.005 from $0.25 to $0.255 per share. BNDS has declared a distribution increase by $0.0025 from $0.34 to $0.3425 per share.

QVOL intends to target an annualized distribution rate range of between 12% and 15% through option premiums earned from selling call options and dividends received from the Fund's equity holdings. This target range reflects Infrastructure Capital's expectations based on the options premiums QVOL seeks to generate and the annualized effect of those premiums. There is no assurance QVOL will achieve its target annualized distribution rate range, and the target annualized distribution rate range does not represent a 12% to 15% yield or a 12% to 15% total return. Actual distributions may be higher or lower depending on market conditions and QVOL's results. Distributions may include a portion classified as return of capital. Return of capital generally represents a return of a shareholder's invested capital rather than traditional income such as dividends or interest.

QVOL has declared a monthly distribution of $1.09 per share ($13.08 per share on an annualized basis). 

- Ex-Date: Tuesday, September 29, 2026

- Record Date: Tuesday, September 29, 2026

- Payable Date: Wednesday, September 30, 2026

SCAP has declared a monthly distribution of $0.255 per share ($3.06 per share on an annualized basis).

- Ex-Date: Tuesday, September 29, 2026

- Record Date: Tuesday, September 29, 2026

- Payable Date: Wednesday, September 30, 2026

ICAP has declared a monthly distribution of $0.255 per share ($3.06 per share on an annualized basis).

- Ex-Date: Tuesday, September 29, 2026

- Record Date: Tuesday, September 29, 2026

- Payable Date: Wednesday, September 30, 2026

BNDS has declared a monthly distribution of $0.3425 per share ($4.11 per share on an annualized basis).

- Ex-Date: Tuesday, September 29, 2026

- Record Date: Tuesday, September 29, 2026

- Payable Date: Wednesday, September 30, 2026

Infrastructure Capital Advisors expects to declare future distributions on a monthly basis. Distributions are planned, but not guaranteed, for every month. For more information about each Fund's distribution policy, its 2026 distribution calendar, or tax information, please visit each Fund's web site for more information.

QVOL is designed to deliver an attractive income stream through a disciplined options-writing strategy, while maintaining the potential for capital appreciation through selective equity positioning. The fund invests at least 80% of its net assets in equity securities and option contracts tied to the Nasdaq, utilizing both quantitative and qualitative analysis to identify relative value opportunities.

"In the current market environment, investors are seeking consistent income without giving up exposure to growth, particularly in the information technology sector," said Jay Hatfield, CEO and CIO of Infrastructure Capital Advisors. "QVOL is built to monetize the increased volatility we've seen across Nasdaq-listed companies through active options strategies while maintaining the careful and pragmatic approach to portfolio and product construction that Infrastructure Capital has become well known for."

Infrastructure Capital's suite of dynamic ETFs leverages the firm's established investment process, including company-level fundamental modeling, valuation-driven price targets, and active volatility management. The firm manages over $4 billion in assets as of 09/28/2026 and delivers income-focused investment solutions to their clients.

QVOL joined the Infrastructure Capital ETF lineup, which includes the Virtus InfraCap U.S. Preferred Stock ETF (NYSE Arca: PFFA), InfraCap REIT Preferred ETF (NYSE Arca: PFFR), InfraCap MLP ETF (NYSE Arca: AMZA), the Infrastructure Capital Equity Income ETF (NYSE Arca: ICAP), Infrastructure Capital Small Cap Income ETF (NYSE Arca: SCAP), Infrastructure Capital Bond Income ETF (NYSE Arca: BNDS) the Infrastructure Capital Preferred Income UCITS ETF (FTSE MIB: PFFI), the Infrastructure Capital S&P 500 Option Income UCITS ETF (FTSE MIB: SPYC), and Infrastructure Capital Nuclear Renaissance UCITS ETF (FTSE MIB: NUKZ).

Hatfield is the lead Portfolio Manager for all of the Infrastructure Capital funds and brings more than 30 years of experience to his work on behalf of clients. As of the date of this release, the firm manages more than $4 billion in total assets.

Follow Infrastructure Capital on social media for all of the firm's need-to-know market commentary and economic outlook at:

Monthly Market and Economic Webinar - Jay Hatfield

Register for our monthly Market & Economic Insights webinar series. Can't join live each month? Register anyway and we will email you a playback video link

Income Investing with Infrastructure Capital

Jay D. Hatfield is the Chief Investment Officer for all of the Infrastructure Capital funds and brings more than 30 years of experience to his work on behalf of clients. As of the date of this release, Infrastructure Capital manages over $4B in total assets. 

BNDS ETF strategy is to target high yield investments across fixed-income securities, predominately focusing on corporate bonds. Infrastructure Capital seeks positive security selection versus the benchmark by using a mix of quantitative and qualitative analysis with an emphasis on fixed-income securities that are believed to be undervalued when considering factors such as term premium, credit premium, liquidity premium, industry, sector, and market capitalization.

SCAP ETF seeks total return through a blended approach of capital appreciation and current income. The Fund focuses primarily on the securities of U.S.-listed small cap companies, which is defined as companies with a market capitalization within the range of companies in the Russell 2000 Index. Investments may take the form of common stocks, preferred stocks, convertible securities, debt instruments, equity-linked notes, or other small cap-focused ETFs.

ICAP ETF will primarily invest in equity securities of companies with a strong track record of paying dividends during normal market conditions. The Fund's portfolio of equities will generally be a diversified selection of securities, including a broad cross-section of sectors and sub-sectors, such as REITs, Utilities, Industrials, pipelines, and financials.

About Infrastructure Capital Advisors

Infrastructure Capital Advisors, LLC (ICA) is an SEC-registered investment advisor that manages exchange traded funds (ETFs) and a series of hedge funds. The firm was formed in 2012 and is based in New York City. ICA seeks total-return opportunities driven by catalysts, largely in key infrastructure sectors. These sectors include energy, real estate, transportation, industrials and utilities. It often identifies opportunities in entities that are not taxed at the entity level, such as master limited partnerships ("MLPs") and real estate investment trusts ("REITs"). It also looks for opportunities in credit and related securities, such as preferred stocks.

Current income is a primary objective in most, but not all, of ICA's investing activities.

Consequently, the focus is generally on companies that generate and distribute substantial streams of free cash flow. This approach is based on the belief that tangible assets that produce free cash flow have intrinsic values that are unlikely to deteriorate over time. For more information, please visit infracapfunds.com.

The information contained herein represents our subjective belief and opinions and should not be construed as investment, tax, legal, or financial advice. Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. Please read the prospectus carefully before investing. For more information about Fund strategies or Infrastructure Capital, please reach out to Craig Starr at 212-763-8336 ([email protected]).

The Nasdaq Composite is a stock market index composed of thousands of stocks listed on the Nasdaq Stock Market®, with a particular emphasis on technology-related companies. Established in 1971, it is known for featuring a wide range of companies—from established giants like Apple and Microsoft to smaller, fast-growing firms—reflecting a broad cross-section of the U.S. technology sector. The index is market capitalization-weighted, meaning that larger companies have a greater influence on its overall performance, and it is commonly used as a benchmark to gauge the health and trends of the technology-driven segments of the American economy.

Investors should consider the investment objectives, risks, charges, and expenses carefully before investing. Please read the prospectus carefully before investing. For more information about the Fund, Fund strategies or Infrastructure Capital, please reach out to Craig Starr at 212-763-8336 ([email protected]).

A word about QVOL Risk: Investing involves risk. Principal loss is possible. The Fund is a recently organized investment company with no operating history prior to the date of this Prospectus. As a result, prospective investors have no track record or history on which to base their investment decision.

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the promotion of Dr. Michael White, from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.

"I am excited to announce this well-deserved promotion for Mike, as President of Research and Development. During Mike's 5-year tenure as Chief Scientific Officer, he has demonstrated exceptional leadership and has been a key driver in advancing IDEAYA's mission to deliver patient impact in areas of high unmet medical need through R&D innovation. Under Mike's leadership, I am excited to see the continued advancement of our industry leading precision medicine oncology pipeline targeting multiple solid tumor indications, including uveal melanoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, colorectal cancer, breast cancer, among others," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences, Inc.

"I am honored to take on this expanded role at such a pivotal time for IDEAYA and grateful for the extraordinary commitment of our research and development teams. We have made tremendous progress in translating our precision medicine capabilities into a deep and differentiated oncology portfolio, with late-stage programs that have the potential to establish new standards of care and early-stage programs that may open entirely new therapeutic opportunities. I am particularly excited by our ability to advance innovative small molecules and antibody-drug conjugates for molecularly defined cancers where patients continue to face significant unmet need. I look forward to building on this momentum and accelerating the delivery of transformative therapies that can meaningfully improve and extend the lives of patients with cancer," said Dr. Michael White, President, Research and Development, IDEAYA Biosciences, Inc.

Dr. White has served as Chief Scientific Officer at IDEAYA Biosciences since 2021. Prior to IDEAYA, Dr. White served as Chief Scientific Officer and Head of Tumor Biology at Pfizer, Inc., where he led cross-disciplinary groups in research and development to build an oncology small-molecule clinical pipeline focused on first-in-class therapies, culminating in numerous INDs and late-stage development programs. Prior to joining Pfizer, Dr. White had a prolific over twenty-year academic career at UT Southwestern where he was a Professor of Cell Biology and founding Director of the Cancer Intervention and Prevention Discovery Program. In 2015, Dr. White received the inaugural Outstanding Investigator's Award from the National Cancer Institute (NCI), the U.S. Government's principal agency for cancer research, and has authored over 150 publications with over 30,000 citations. Dr. White received his Ph.D. in Biology from the University of North Carolina at Chapel Hill and completed postdoctoral research at Cold Spring Harbor Laboratories in New York.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding IDEAYA's research and development strategy and objectives; the expected contributions of Dr. Michael White in his expanded role as President, Research and Development; the continued advancement of IDEAYA's precision medicine oncology pipeline; the potential of IDEAYA's late-stage programs to establish new standards of care and its early-stage programs to create new therapeutic opportunities; IDEAYA's ability to develop and advance innovative small-molecule therapies and antibody-drug conjugates for molecularly defined cancers; and the potential for IDEAYA's product candidates to improve and extend the lives of patients with cancer.

These forward-looking statements are based on management's current expectations and assumptions and are subject to a number of risks, uncertainties, and other factors that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to: risks related to the timing, progress, and results of clinical trials and preclinical studies; the ability of IDEAYA to obtain and maintain regulatory approvals; uncertainties regarding the regulatory review process, including participation in the RTOR program; the potential for clinical data to differ from preliminary or interim results; the ability to successfully develop, manufacture, and commercialize product candidates; competition from other biotechnology and pharmaceutical companies; the impact of global economic conditions; IDEAYA's ability to successfully establish, protect and defend its intellectual property: and other risks described in IDEAYA's filings with the U.S. Securities and Exchange Commission (SEC), including its most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K.

Forward-looking statements speak only as of the date of this press release, and IDEAYA undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Investor and Media Contact

IDEAYA Biosciences

Joshua Bleharski

Chief Financial Officer

[email protected]

SOURCE IDEAYA Biosciences, Inc.

Share this article

New AI-powered capability helps agencies manage caregiver call-offs, missed clock-ins, and critical communications around the clock

WACO, Texas, Sept. 28, 2026 /PRNewswire/ -- AxisCare, a leading provider of home care management software, today announced the release of Axi Assist, an AI-powered receptionist designed to help home care agencies manage critical communications 24/7, reduce the burden of on-call staffing, and take faster action when operational needs arise.

Built directly into the AxisCare platform, Axi Assist can answer calls, capture information, initiate workflows, and escalate situations when human involvement is needed.

One of its first applications addresses a persistent challenge for home care agencies: caregiver call-offs. When a caregiver calls to report that they cannot make a shift, Axi Assist captures the details and gets the scheduling process moving right away. The capability can also handle calls after hours, including nights, weekends, and holidays, helping agencies respond to important issues that might otherwise sit in voicemail until a coordinator is available.

Axi Assist also helps agencies address missed clock-ins through automated caregiver outreach that begins one minute after the start of their shift. The outreach happens within the window where a caregiver can still clock themselves in on time, helping visits stay compliant and billable while reducing the need for office staff to chase down missed clock-ins.

"AI is most valuable when it lives where the work happens and has the context to help people take action," said John Atkinson, CTO & COO of AxisCare. "Axi Assist is a great example of that. It takes repetitive, time-sensitive work off teams' plates while keeping people involved when their judgment and expertise are needed."

Axi Assist is the latest addition to the AxisCare Intelligence AI-Powered Suite, adding to capabilities like Care Analytics and Scheduling, along with the newly introduced AI Form Transcription, expanding AxisCare's vision for an all-in-one, AI-powered System of Action that goes beyond recording what happened to help agencies determine what needs to happen next and move work forward.

"Axi Assist represents where we see AI heading in home care," Atkinson added. "The opportunity isn't adding AI for the sake of AI. It's embedding AI into the workflows agencies already use every day, helping teams take action faster and spend more time focused on delivering the best care possible."

Axi Assist is now available.

Click here to learn more about AxisCare Intelligence AI-Powered Suite.

About AxisCare: AxisCare is the leading all-in-one operating system for single and multi-location home care agencies, serving more than 4,500 providers across all 50 states and seven countries. Built for Private Pay, Skilled Care, IDD, Medicaid, and VA programs, AxisCare unifies scheduling, care delivery, compliance, billing, and revenue cycle management into a connected System of Action across every stage of care. Through automation, operational intelligence, and a suite of AI-powered capabilities, AxisCare helps agencies streamline operations, strengthen financial performance, accelerate growth, and stay focused on what matters most: delivering exceptional care in the home. For more information, visit axiscare.com.

SOURCE AxisCare

Share this article

New Capability Brings Discovery, Access Control, and Runtime Protection to Agents, MCP Servers, and Skills Running on Employee Machines

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Noma, the market-leading enterprise AI and agent security platform, today announced expanded endpoint agent security capabilities across the Noma Platform. The endpoint has become one of the largest blind spots in enterprise AI security; with agents, MCP servers, and skills already running on employee laptops carrying the same permissions and credentials as the people who installed them. Noma's new capabilities discover the agents, MCP servers, and skills running on employee machines, enforce access control over what each is allowed to do, and use AI Detection and Response (AI-DR) to block dangerous behavior at runtime. Policy and context now follow each agent between SaaS, homegrown, and endpoint environments, giving security teams one control plane across the entire agent estate.

Developers use coding agents such as Claude Code, Cursor, Codex, and Windsurf to work with source code and production infrastructure. Business users rely on productivity agents such as Claude Cowork to work with documents, browsers, SaaS applications, and internal data. MCP servers and skills extend that reach into databases, repositories, and other systems. Agents can chain those actions together across a session without human approval at every step, and that access already exists before any attacker is ever involved.

The risk does not require an exploit. A security researcher recently found that xAI's Grok Build coding assistant was uploading entire tracked repositories and their full Git history to the provider's cloud, even after being explicitly instructed not to open any files. Approving an agent is not enough. Security teams need a way to find new agents as they arrive and enforce policy while those agents act. Noma's shared Runtime Context Engine ties identity, permissions, policy, and behavior together into one signal.

Discovery and Governance

Endpoint activity leaves local evidence in configuration files, skills directories, connector history, and running processes. Noma connects through the EDR or MDM already in place to turn that evidence into a live inventory of agents, MCP servers, skills and connected accounts across managed devices.  Noma continuously assesses those assets for risks such as secrets in agent instructions, unsandboxed execution and excessive agency.

That inventory feeds directly into Noma Access Control, turning agents and tools already present on employee machines into governed assets. Access Control brings together three capabilities:

- Governed Registry - Every agent, MCP server, and skill receives a clear status: approved, needs review, or blocked, with newly discovered assets entering the registry automatically.

- Identity-Aware Policy - Noma attributes each agent to the human behind it and connects that identity to IdP users and groups, so policy can be enforced by user, group, tool, or organization-wide.

- Tool- and Action-Level Control - Policies can govern the agent, MCP server, skill, individual tool, and action, so read access can stay broadly available while create, update, or delete operations remain limited to a smaller group.

Runtime Protection with AI-DR

AI-DR is Noma's runtime threat protection layer. It monitors the skills, MCP servers, and tools agents actually use, establishes a baseline for agent behavior, and detects prompt injection, sensitive data leakage, malicious intent, tool poisoning, scope violations, and agents drifting from their intent or established behavior. Noma's Contextual Policies extend that protection across full sessions, correlating prompts, tool calls, tool responses, data access, identity and behavior over time. This allows Noma to identify threats that develop across a sequence of otherwise permitted actions. Every detector is independently tunable to monitor, alert, steer, block, mask sensitive data inline, or route an action to a human. Coverage must follow the agent past the laptop, since an approved database or API tool can turn a routine task into mass deletion.

"Agents on the endpoint carry some of the most privileged identities in the company, often unnoticed by security until something goes wrong," said Niv Braun, CEO and Co-Founder of Noma Security. "Extending our access control and AI-DR model to the endpoint means security teams get the same visibility and enforcement they already have across SaaS and homegrown agents, in the place agents are proliferating fastest."

Noma Open Enforcement applies these policies across the architecture organizations already run, including agent hooks, AI and MCP gateways, SDKs, and EDR and MDM, with coverage spanning agents including Claude Code, Claude Cowork, Cursor, Codex, Windsurf, Kiro, Antigravity, and OpenClaw. Organizations start with hundreds of AI-DR policies and protection profiles tuned by industry and agent type, reflecting work with dozens of Fortune 500 security teams. Noma also plans to bring Agent Boundaries, which enforce business-defined limits on agent actions, to the endpoint.

To learn more about how Noma secures agents at the endpoint, visit https://noma.security/platform/endpoint-agents.

About Noma

Noma is the AI and agent security platform purpose-built for the enterprise. Noma detects behavioral threats, governs what agents are allowed to do, and protects AI across every environment where agents run: homegrown applications built on AWS Bedrock, Azure AI Foundry, and Databricks; SaaS agent platforms like Microsoft Copilot Studio and Salesforce AgentForce; and prebuilt agents like Claude Code, Cursor, and GitHub Copilot running on developer machines. Backed by Evolution Equity Partners, Ballistic Ventures, Glilot Capital, Cyber Club London, Databricks Ventures, and SVCI, Noma is widely adopted by Fortune 500 customers and has been recognized by Gartner as a leader in AI trust, risk, and security management (AI TRiSM). Learn more at https://noma.security and follow us on LinkedIn.

Media Contact 

ICR for Noma

[email protected]

SOURCE Noma Security

Share this article

111, Inc. Announces Establishment of the Special Committee

SHANGHAI, Sept. 28, 2026 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising of three independent directors, Mr. Jian Sun, who is the chairman of the Special Committee, Mr. Nee Chuan Teo and Mr. Jun Luo, has been established by the Company's Board of Directors to consider and evaluate the previously announced preliminary, non-binding proposal letter dated September 16, 2026 (the "Proposal") as well as other potential strategic alternatives that the Company may pursue.

The Board cautions the Company's shareholders and others considering trading the Company's securities that no decisions have been made with respect to the Proposal or any alternative strategic option that the Company may pursue. There can be no assurance that any definitive offer will be received, that any definitive agreement will be executed relating to the transaction contemplated by the Proposal or that any other comparable transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to any transaction, except as required under applicable law.

Forward-Looking Statements

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market, including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

About 111

111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading technology-enabled healthcare platform transforming China's healthcare value chain through digitalization and artificial intelligence (AI). By connecting consumers, pharmacies, pharmaceutical companies and other healthcare participants, 111 aims to make pharmaceutical products and healthcare services more accessible, efficient and affordable, while helping industry participants operate more intelligently.

Through its integrated ecosystem, 1 Pharmacy, the Company's online retail pharmacy, provides consumers with convenient access to a broad range of pharmaceutical products and healthcare services. On the B2B side, 1 Medicine offers pharmacies a one-stop digital sourcing platform, helping them improve purchasing efficiency, product availability and inventory management. Leveraging its pharmacy network, proprietary industry data and digital infrastructure, 111 is increasingly deploying AI-powered solutions and Agents to help pharmacies manage daily operations, including sales analysis, inventory optimization, replenishment, pricing and promotions. For pharmaceutical and healthcare companies, 111 provides an omni-channel commercialization platform combining digital marketing, patient education, data analytics, pricing and market monitoring.

111 is transforming from a digital company into an AI-powered healthcare company. Using its industry data and digital capabilities, the Company deploys AI Agents that move beyond information and analysis to execute workflows for pharmacies and other industry participants. With AI models, proprietary healthcare data and interconnected business systems, 111 aims to build an intelligent operating layer for healthcare and strengthen its role as a tech platform linking China's healthcare value chain upstream and downstream.

For more information on 111, please visit: http://ir.111.com.cn/.

For more information, please contact:

111, Inc.

Investor Relations

Email: [email protected] 

111, Inc.

Media Relations

Email: [email protected] 

Phone: +86-021-2053 6666  (China)

SOURCE 111, Inc.

Share this article

Teleste Adds Authorized Repair Services to Its Growing North American HFC Ecosystem

Fiber Node Services adds a U.S.-based path for warranty and out-of-warranty repairs, complementing Teleste's established regional manufacturing, assembly, sales and technical support.

TURKU, Finland and CAROL STREAM, Ill., Sept. 28, 2026 /PRNewswire/ -- North American cable operators now have an additional, manufacturer-authorized route for servicing Teleste Networks hardware. Teleste has appointed and trained Fiber Node Services, Inc. (FNS) as an authorized provider of warranty and out-of-warranty repairs through its U.S. repair network.

The authorization covers all Teleste Networks hardware sold in North America. It adds regional repair to a North American operating footprint that already spans manufacturing, customer-specific assembly, sales and technical support.

Teleste has supported North American operators locally for years through dedicated sales and technical support teams, backed by the company's engineering, manufacturing and supply capabilities in Europe. Its regional footprint also includes high-volume production of the ICON amplifier family through GPV Americas in Mexico and customer-specific assembly at Teleste's New Jersey distribution center.

"For operators, local presence should not end when equipment is delivered," said Steve Condra, Senior Vice President of North America Sales for Teleste. "It should mean capacity when deployments grow, technical expertise when it is needed and a practical repair route throughout the life of the equipment. We have built those capabilities step by step in North America. Authorized service through FNS adds another important layer."

By combining production in Europe and Mexico with assembly in the United States, Teleste can increase available output, shorten transportation paths for North American deliveries and retain multiple supply options as demand changes. FNS adds qualified U.S. repair capacity connected directly to Teleste's product and engineering expertise.

FNS has specialized in the diagnostics, repair and refurbishment of CATV broadband equipment for more than 30 years. Following qualification and product-specific training by Teleste, its technicians are authorized to diagnose, repair and test Teleste Networks hardware according to Teleste's procedures and requirements.

"Effective repair depends on more than having a repair bench close to the customer," said Zoran Beric, CEO and President of Fiber Node Services. "It takes broadband experience, product-specific knowledge and a direct connection to the manufacturer. Our teams have already provided repair services for Teleste equipment in North America, and this authorization builds on that work. We will continue giving operators regional support for both warranty and out-of-warranty needs."

Together, these capabilities give North American operators a shorter path to the products, people and services behind their networks—from supply and configuration through technical support and repair—while retaining access to Teleste's broader global engineering, manufacturing and supply resources.

About Fiber Node Services

Fiber Node Services, Inc. (FNS) was founded in 1993 and specializes in diagnostics, repair, refurbishment and calibration services for CATV broadband equipment. Headquartered in Carol Stream, Illinois, FNS operates repair facilities across the United States and provides services to broadband operators and equipment manufacturers.

For more information, please visit www.fibernode.com.

About Teleste

Teleste (HEL: TLT1V) offers an integrated portfolio of products and services that helps build and run a better-networked society. Our solutions deliver broadband and television services, enhance safety in public places, and support the use of public transport. With solid industry expertise and a strong drive for innovation, we are a leading international company in broadband, security and information technologies and related services. We connect with our customers through a global network of offices and partners. Teleste is listed on Nasdaq Helsinki. For more information, please visit www.teleste.com.

Media inquiries

Teleste — Linda Kallas, SVP, Communications, [email protected]

This information was brought to you by Cision http://news.cision.com.

SOURCE Teleste Corporation

Share this article